Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230024/S001

Flow FL-100

Flow Neuroscience AB · Decision date Jul 14, 2026

FDA DECISIONP230024/S001

What did the FDA approve?

FDA records P230024/S001 as a supplement to PMA P230024, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Jul 14, 2026.

FDA approval order statement

approval for minor device design changes, editorial and maintenance updates to existing firmware, server and application documentation, clarification updates to accessory pad specifications, and a minor mechanical design change.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Neurology
Decision date
Jul 14, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P230024/S001
Regulatory pathway
PMA supplement
Product code
JXK
Decision code
APPR
Decision date
Jul 14, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Cranial electrotherapy stimulator to treat depression.

Product code
JXK
FDA device class
3

For the original device and its historical approval scope, see PMA P230024. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230024/S001 received

    Application receipt date recorded by FDA.

  2. P230024/S001 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P230024. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230024

Product / regulatory recordCompanyPathwayDecision dateSource
Flow Neuroscience ABPMA approvalDec 8, 2025FDA

Explore the linked device profile

Other records with product code JXK

Product / regulatory recordCompanyPathwayDecision dateSource
Neurolief , Ltd.PMA approvalDec 31, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Flow Neuroscience AB

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
470 Ramona St., Palo Alto, CA, 94301

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records